Paul Y F Lee

Prof. Paul Y F Lee

Sports Medicine, College of Health and Science, University of Lincoln, Lincoln, Lincolnshire, UK
orcid
Consultant Orthopaedic Surgeon, MSK Doctors. Honorary Profe...

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The Surgery Journal
Verified
Journal Article
Open access
PDF file
Paul Y F LeePaul Y F Lee
Paul Y F Lee
ANAmy Nixion
Amy Nixion
ACAmit Chandratreya
Amit Chandratreya
JMJudith M. Murray
Judith M. Murray
Synovial plica syndrome (SPS) occurs in the knee, when an otherwise normal structure becomes a source of pain due to injury or overuse. Patients may present to general practitioners, physiotherapists, or surgeons with anterior knee pain with or without mechanical symptoms, and the diagnosis can sometimes be difficult. Several studies have examined the epidemiology, diagnosis, and treatment of SPS. We review these resources to provide an evidence-based guide to the diagnosis and treatment of SPS of the knee.

26 January 2011 in International Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
Paul Y F LeePaul Y F Lee
Paul Y F Lee
ARA. Rattenberry
A. Rattenberry
SCS. Connelly
S. Connelly
LNL. Nokes
L. Nokes
Muscle injuries are one of the most common sport related injuries, their incidence varying from 30–55% in all sports injuries. They account for the loss of 90 training days and 15 matches per club per season in elite football (soccer). In recent years, the use of Actovegin® in sports medicine has caused a lot of controversy in many sports disciplines. Although it is unlikely for this deproteinised substance to have oxygen-enhancing capacity, there is an anecdotal belief that Actovegin® can increase an athlete's performance. Actovegin® is produced by Nycomed Austria GmbH and has been used by doctors across Europe, China and Russia for over 60 years. Nevertheless, very little is known regarding the effects of Actovegin on muscle injuries. This article reviews the current evidence on Actovegin®, its legal status with sports governing bodies and its potential role in sport injuries. We will also report our experience with this drug in treating muscle injuries. In this pilot study, players in the Actovegin treatment group were able to return to play 8 days earlier (95% CI −1.249 to −14.7510) compared to physiotherapy alone (p=0.033). No adverse reactions were recorded in any of the participants.

30 March 2016 in HIP International
Verified
Journal Article
Closed access
KTKar H. Teoh
Kar H. Teoh
Paul Y F LeePaul Y F Lee
Paul Y F Lee
DWDavid J. Woodnutt
David J. Woodnutt
Purpose: Although there have been several varieties of short-stem hip prosthesis in the market, there have been no published clinical results of the Corin MiniHip (Corin, Cirencester, UK) to date. The aim of this study is to describe our early results and experience of this stem in a nondesigner, single-surgeon series; calculate 5-year survival with stem revision as an endpoint; evaluate complications and early revisions; and assess radiolucency and stem subsidence at the latest follow-up review. Methods: Over a 5-year period, 275 MiniHip were implanted in 239 patients. The mean age of the patients was 63 years (range 20-84); mean follow-up was 37 months (range 12-72 months). Results: The mean Harris Hip Score and Oxford Hip Score improved significantly to 87 (range 49-100) and 41 (range 32-48) at the final follow-up (p = 0.038; p = 0.017). There were 9 intraoperative calcar fractures (3%) of which only 1 required cerlage wiring. 10 patients died in our series and none were lost to follow-up. 2 patients had their stem revised for failure of fixation (secondary to possible undersizing) and sink. The risk of revision was 0.73% at 5 years. The Kaplan Meier estimate of survivorship of cumulative failure gave an implant survival rate of 99.3% (95% confidence interval [CI], 27.0-100) at 5 years for revision for any reason as the endpoint. Conclusions: This novel, short-stem prosthesis has shown good survival in the short term, similar to other short-stem prostheses currently available. We describe the largest series in the literature of this prosthesis.

1 July 2011 in Optometry and Vision Science
Verified
Journal Article
Closed access
Paul Y F LeePaul Y F Lee
Paul Y F Lee
AKAlvin Kwan
Alvin Kwan
LNLen Nokes
Len Nokes
Actovegin is a deproteinized serum extract of bovine origin, and in recent years it has been used widely in treating sport injuries with many anecdotal reports of success. However, the use of Actovegin in sport medicine has caused a substantial amount of controversy, especially concerning its supposed oxygen-enhancing capacity and an anecdotal belief that its use can increase an athlete's performance. In 2009, a sports physician was arrested with this "performance-enhancing drug," while an editorial in a sports medicine journal strongly questioned the evidence base for using this drug for acute muscle injury. There is also a report that suggested that Actovegin might have induced anaphylactic shock in a cyclist. In this review, we have systematically examined the current evidence on Actovegin. Its mechanism of action, clinical evidence, legal status with sports governing bodies, and its potential role in sport injuries will be discussed.

23 January 2024 in Frontiers in Digital Health
Verified
Journal Article
Open access
PDF file
KAKai Armstrong
Kai Armstrong
LZLei Zhang
Lei Zhang
YWYan Wen
Yan Wen
AWAlexander P Willmott
Alexander P Willmott
Paul Y F LeePaul Y F Lee
Paul Y F Lee
Xujiong YeXujiong Ye
Xujiong Ye
In recent years the healthcare industry has had increased difficulty seeing all low-risk patients, including but not limited to suspected osteoarthritis (OA) patients. To help address the increased waiting lists and shortages of staff, we propose a novel method of automated biomarker identification and quantification for the monitoring of treatment or disease progression through the analysis of clinical motion data captured from a standard RGB video camera. The proposed method allows for the measurement of biomechanics information and analysis of their clinical significance, in both a cheap and sensitive alternative to the traditional motion capture techniques. These methods and results validate the capabilities of standard RGB cameras in clinical environments to capture clinically relevant motion data. Our method focuses on generating 3D human shape and pose from 2D video data via adversarial training in a deep neural network with a self-attention mechanism to encode both spatial and temporal information. Biomarker identification using Principal Component Analysis (PCA) allows the production of representative features from motion data and uses these to generate a clinical report automatically. These new biomarkers can then be used to assess the success of treatment and track the progress of rehabilitation or to monitor the progression of the disease. These methods have been validated with a small clinical study, by administering a local anaesthetic to a small population with knee pain, this allows these new representative biomarkers to be validated as statistically significant (p-value <0.05). These significant biomarkers include the cumulative acceleration of elbow flexion/extension in a sit-to-stand, as well as the smoothness of the knee and elbow flexion/extension in both a squat and sit-to-stand.

8 February 2012 in International Journal of Sports Medicine
Verified
Journal Article
Closed access
Paul Y F LeePaul Y F Lee
Paul Y F Lee
LNL. Nokes
L. Nokes
PSP. M. Smith
P. M. Smith
There is much speculation that Actovegin® is ergogenic, but no scientific work has been published in this field. 8 participants [mean(± SD) age, height and mass of 24 (7) years, 1.76 (0.07) m and 80.1 (9.1) kg, respectively] completed 3 exhaustive arm crank ergometry tests. Following Baseline testing 2 further tests were performed 2 h following the injection of either 40 ml of Actovegin® or a saline Placebo. Peak power (Wpeak), peak physiological responses, concentrations of blood glucose and lactate, exercise efficiency (%), VO2 gain (ml·W-1), and the respiratory compensation point (RCP) were determined. Repeated measures ANOVA tests were used to analyse data with significance accepted at p≤0.05. Values of mean (±90% CI) bias were calculated to further explore quantitative differences between trials. Strong trends for variations in Wpeak (p=0.054) and RCP (p=0.054) were evident; likely meaningful effects existed between the Baseline and both injection trials, but only a trivial effect was noted between Placebo and Actovegin® (bias: Wpeak 0.8±3.2 and RCP; 2.5±4.7 W). Concentrations of blood lactate and glucose changed across time, but did not differ between the 3 trials. Our data suggests the Actovegin® is not ergogenic and did not influence functional capacity in the context of the exhaustive, upper-body test employed.